Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkersAdditional data to be presented throughout 2024, including in vitro and in vivo data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Ca
Related Keywords
Netherlands , San Diego , California , United States , Sarah Kiely , Peter Kelleher , Gerard Platenburg , Eli Lilly , Robert Stanislaro , Exchange Commission , International Conference On Base Editing , International Conference , Base Editing , Prime Editing , Related Enzymes , Chief Scientific Officer , Editing Oligonucleotides , Adenosine Deaminase Acting , Looking Statements , Rna Editing , Proqr Therapeutics , Na Oligonucleotides , Dna Analysis , Preclinical Data , Potential ,
comparemela.com © 2020. All Rights Reserved.